Lv4
530 积分 2024-10-17 加入
Site-specific or empirical chemotherapy for cancer of unknown primary: the right answer?
2小时前
已完结
177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial
18天前
已完结
皖公网安备34019202002308
